Pfizer-BioNTech COVID-19 Vaccine

close up of syringe

General Information:
Vaccine: Pfizer-BioNTech COVID-19 Vaccine
Diluent: 0.9% sodium chloride (normal saline, preservative-free)

Vaccine MUST be mixed with diluent before administration.
Multidose vial: Up to 6 doses per vial
Dosage: 0.3 mL

Age Indications:
16 years of age and older

Schedule:
2-dose series separated by 21 days)
A series started with COVID-19 vaccine (Pfizer) should be completed with this product.

Administer:
Intramuscular (IM) injection in the deltoid muscle

Administration Overview

Before administering vaccine, screen recipients for contraindications and precautions, even if this is the second dose. The recipient’s health condition or recommendations regarding contraindications and precautions for vaccination may change from one visit to the next.

To assess recipients correctly and consistently, vaccination providers should use a standardized, comprehensive screening tool.

Contraindications and Precautions
How to Thaw, Prepare, and Administer the Pfizer-BioNTech Vaccine
laptop solid icon
Document the Vaccination

COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration and use their best efforts to report administration data to the relevant system for the jurisdiction (i.e., immunization information system) as soon as practicable and no later than 72 hours after administration.

Storage and Handling Overview
weather icon

 Store vaccine in an ultra-cold freezer, thermal shipping container, or refrigerator.
See guidance below for each storage unit.

  • Vaccine will arrive at a temperature between -80°C and 60°C (-112°F to -76°F) in a thermal shipping container with dry ice. The diluent and ancillary supply kits are packaged separately from the vaccine.
  • Unpack the thermal shipping container following the manufacturer’s directionsexternal icon.
How to Store the Pfizer-BioNTech COVID-19 Vaccine
comment alt lines light icon
Report Adverse Events

Adverse events that occur in a recipient after COVID-19 vaccination are required to be reported to the Vaccine Adverse Event Reporting System (VAERS). FDA requires vaccination providers to report vaccine administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration of COVID-19 vaccine under an EUA. Reporting is encouraged for other clinically significant adverse events, even if it is not clear that a vaccine caused the adverse event. Complete and submit reports to VAERS onlineexternal icon.

For further assistance with reporting to VAERS, call 1-800-822-7967.

hand holding medical light icon
What to Expect after a COVID-19 Vaccination

Print informationpdf icon for your patients on common side effects, helpful tips, and when to call a doctor after a COVID-19 vaccination.

email_03Get Email Updates

To receive email updates about this page, enter your email address:

Page last reviewed: January 4, 2021